A Look At Latest Figures On R&D For Neglected Diseases 01/03/2017 by Kim Treanor for Intellectual Property Watch 2 Comments Financing for research and development into so-called neglected diseases – those predominantly affecting lower-income populations – rose recently mainly due to the Ebola outbreak, and private sector contributions represent a bigger share, according to the latest available data from a Gates Foundation-supported database.
Rare Diseases: Pharma Industry Calls For Collaboration, Political Commitment For Research 01/03/2017 by Intellectual Property Watch 2 Comments Big Pharma wants to develop treatments for rare diseases, with government support. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) this week launched a new report describing policy priorities to increase research and development into rare diseases.
Global Fund Hits Reset On Executive Director Search 28/02/2017 by William New, Intellectual Property Watch 4 Comments The Global Fund to Fight AIDS, Tuberculosis and Malaria is deliberating on how to start over on its search for a new executive director after questions arose near the end of the process.
Many Questions On Potential Multilateral Investment Court System 27/02/2017 by Monika Ermert for Intellectual Property Watch 2 Comments The European Commission is pushing ahead with its Multilateral Investment Court (MIC) project, but called requests to eliminate specialised investor protection mechanisms unrealistic during a dedicated meeting with stakeholders in Brussels today.
South Centre Paper Sees IP In Free Trade Agreements Interfering With UN SDGs 27/02/2017 by Kim Treanor for Intellectual Property Watch 1 Comment A new paper from the intergovernmental South Centre argues that intellectual property provisions in recent free trade agreements would impair countries trying to fulfil the United Nations Sustainable Development Goals. Image Credits: South Centre
WHO Issues First List Of Potential Deadly Bacteria If No New Antibiotics Are Found 27/02/2017 by Catherine Saez, Intellectual Property Watch 1 Comment Microbial resistance to antibiotics has been rising and the world is now facing the serious possibility of falling back to the days when infectious diseases were hardly treatable. The World Health Organization today published a list of bacteria for which new antibiotics are most urgently needed, to help with the race against time, as the medical world is running out of treatment options.
WIPO Committee On Protection Of Folklore: Shall We Dance? 24/02/2017 by Catherine Saez, Intellectual Property Watch 3 Comments It is generally held that traditional cultural expressions reflect communities’ cultural and social background and include elements of their heritage. For indigenous and local communities, those expressions of their traditional culture are vital. Next week, World Intellectual Property Organization committee members are expected to advance on a draft treaty text to protect those expressions, and look for ways to agree on basic principles, such as what the treaty should protect, how, and who it should protect.
More Transparency In Medical Product Prices Discussed At Event 24/02/2017 by Catherine Saez, Intellectual Property Watch 2 Comments The lack of access to medical products has spread from being a developing country problem to a global one as prices are now too high even for developed country patients and health systems for some medicines. An event at the Graduate Institute Global Public Health Centre yesterday was an opportunity to explore these issues.
German-Backed Report Lays Out Strategy For R&D Into New Antibiotics 23/02/2017 by Catherine Saez, Intellectual Property Watch 1 Comment In the face of the lack of attractiveness of investing in research for new antibiotics for the pharmaceutical industry, and the general lack of funding for research and development for novel antibiotics, a new report commissioned by the German Federal Ministry of Health calls for countries to take action. In particular, the report proposes a global union for research and development, a global research fund, and a global launch reward. And access and pricing are key components of the strategy, it says.
US Business, Government Work To Bring Down ‘Dangerous’ UN Panel Report On Access To Medicines – And Change The Debate In Geneva 23/02/2017 by William New, Intellectual Property Watch 3 Comments Calling it flawed and narrow and seemingly threatened by its contents, the leading United States business group and US government IP specialists are working to limit the impact of a recent United Nations report that made recommendations for the decades-old problem of ensuring affordable medicines reach people when they are under patent in a way that does not threaten innovation. One step in countering the UN report? Change the discourse in Geneva and elsewhere.